Other assets

3 Months Ended

Mar. 31, 2024

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Other assets

Note 5 – Other assets

	March 31, 2024		December 31, 2023
License, net	$	2,627,870	$	2,702,064
Deposit		4,123		4,123
Licenses, net	$	2,631,993	$	2,706,187

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2024

As of June 1, 2019, we entered into a license agreement, which will be amortized over the life of the Patent. The Patent expires December 31, 2032. The Exclusive Patent License to the Jadi Cell is for use under the designated areas of CTE (Chronic Traumatic Encephalopathy), and TBI (Traumatic Brain Injury). The Jadi Cell is an cGMP grade and Research grade manufactured allogenic mesenchymal stem cells derived from US Patent No.: 9,803,176 B2.

Prepaid consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above consists of the following:

	March 31, 2024			December 31, 2023
License	$	3,261,122		$	3,261,122
Accumulated amortization		(633,252	)		(559,058	)
Licenses, net	$	2,627,870		$	2,702,064

Amortization expense for the three months ended March 31, 2024, and 2023 was $74,194 and $74,194, respectively.